BR112014005210A2 - uso de 1h-quinazolina-2,4-dionas para uso na prevenção ou tratamento da epilepsia fotossensível - Google Patents

uso de 1h-quinazolina-2,4-dionas para uso na prevenção ou tratamento da epilepsia fotossensível

Info

Publication number
BR112014005210A2
BR112014005210A2 BR112014005210A BR112014005210A BR112014005210A2 BR 112014005210 A2 BR112014005210 A2 BR 112014005210A2 BR 112014005210 A BR112014005210 A BR 112014005210A BR 112014005210 A BR112014005210 A BR 112014005210A BR 112014005210 A2 BR112014005210 A2 BR 112014005210A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
quinazoline
dione
photosensitive epilepsy
Prior art date
Application number
BR112014005210A
Other languages
English (en)
Portuguese (pt)
Inventor
Johns Donald
Imbert George
Kucher Klaus
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014005210A2 publication Critical patent/BR112014005210A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014005210A 2011-09-07 2011-09-07 uso de 1h-quinazolina-2,4-dionas para uso na prevenção ou tratamento da epilepsia fotossensível BR112014005210A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
BR112014005210A2 true BR112014005210A2 (pt) 2017-03-21

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005210A BR112014005210A2 (pt) 2011-09-07 2011-09-07 uso de 1h-quinazolina-2,4-dionas para uso na prevenção ou tratamento da epilepsia fotossensível

Country Status (10)

Country Link
EP (1) EP2753331A1 (enExample)
JP (1) JP2014525474A (enExample)
KR (1) KR20140071405A (enExample)
CN (1) CN103889427A (enExample)
AU (1) AU2011376333A1 (enExample)
BR (1) BR112014005210A2 (enExample)
CA (1) CA2846503A1 (enExample)
IN (1) IN2014DN01791A (enExample)
MX (1) MX2014002693A (enExample)
WO (1) WO2013036224A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CA2549965A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
WO2005044267A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
CA2549967A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
CN1933838A (zh) 2004-02-12 2007-03-21 默克公司 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
EP2496220B1 (en) * 2009-11-03 2019-10-16 Lupin Limited Modified release formulation of lacosamide

Also Published As

Publication number Publication date
MX2014002693A (es) 2014-06-04
WO2013036224A1 (en) 2013-03-14
AU2011376333A1 (en) 2014-03-13
CN103889427A (zh) 2014-06-25
CA2846503A1 (en) 2013-03-14
EP2753331A1 (en) 2014-07-16
KR20140071405A (ko) 2014-06-11
IN2014DN01791A (enExample) 2015-05-15
JP2014525474A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
ECSP13012379A (es) Pirimidinas y triazinas condensadas y su uso
CL2013001295A1 (es) Compuestos derivados de 2,3-dihidromidazo (1,2-c) quinazolina sustituidos con aminoalcoholes; compuesto intermediario y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
BR112014014769A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou sal.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014017968A8 (pt) Compostos de beta-lactama substituídos por amidina, sua preparação e uso como agentes antibacterianos
DOP2014000160A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
BR112014030406A2 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica
ES2569743R1 (es) Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
GT201400161A (es) Fenilimidazopirazoles sustituidos y su uso
EP2771346A4 (en) ISOXAZOLOPYRIDIN-orexin
BR112013017184A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]